SB-007 for stargardt disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Feb 2025: Trial started, NCT06942572
  2. 24 Apr 2025: Trial registered, NCT06942572

The trials

NCT06942572: A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

State
Under way
Phase
Phase 1 and Phase 2
People
57 planned
Started
11 Feb 2025
Primary completion
31 Oct 2028
Arms
Phase 1 Dose Escalation - Low Dose, Phase 1 Dose Escalation - Medium Dose, Phase 1 Dose Escalation - High Dose, Phase 2 Dose Expansion: Dose 1 from Phase 1 Randomised Arm, Phase 2 Dose Expansion: Dose 2 from Phase 1 Randomised Arm
Results
None posted
  1. 11 Feb 2025: Trial started
  2. 24 Apr 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.